NVO:NYSE
Novo Nordisk A/S
46,60 $
arrow_downward
-1,92%(-0,91) 1 d.
46,50 $
arrow_downward
-0,21% (-0,100)bedtimePēctirdzniecības
Slēgts: 4. sept., 16:00:08 GMT-4 · USD
search
Visi simboli
1 d.
5 d.
1 m.
6 m.
Š.g.
1 g.
5 g.
Maks.
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: NVO…
Atvērt
46,35 $
Augsta
46,74 $
Zema
46,04 $
Tirgus kapitalizācija
158,02 mljrd.
Vid. apjoms
13,01 milj.
Apjoms
6,22 milj.
Dividende
3,86%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
11,48
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
4,06 $
Beta
0,73
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
46,35 $
Augsta
46,74 $
Zema
46,04 $
Tirgus kapitalizācija
158,02 mljrd.
Vid. apjoms
13,01 milj.
Apjoms
6,22 milj.
Dividende
3,86%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
11,48
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
4,06 $
Beta
0,73
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Simply Wall Street
·
pirms 25 minūtēm
Novo Nordisk (NVO) Stock May Be Below Fair Value After GLP 1 Legal News
Yahoo Finance
·
pirms 11 stundām
Novo Nordisk (CPSE:NOVO B) Stock Looks Below Fair Value But Faces Earnings Doubts
TipRanks
·
pirms 14 stundām
Novo Nordisk Refines Its Obesity Pipeline With New Cagrilintide Study Update
AD HOC NEWS
·
pirms 14 stundām
Novo-Nordisk stock benefits from Wegovy tablet launch as obesity focus grows
Profils
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
Par “Novo Nordisk A/S”
ĢenerāldirektorsMaziar Mike Doustdar
Darbinieki66,7 tūkst.
Dibināšanas datums1923. gada 21. dec.
Galvenais birojsBagsværd, Galvaspilsētas reģions, Dānija
Sektors-
Tīmekļa vietnenovonordisk.com